Viking Therapeutics Inc Stock

Are you looking for a top growth stock to buy heading into 2026? Although valuations are high for many stocks, there are some potential deals still out there right now.

Three stocks that haven't

There's an old saying that a rising tide lifts all ships. Ironically enough, the adage doesn't apply to cruise line stocks. Norwegian Cruise Line (NYSE: NCLH) is once again the worst-performing

Novo Nordisk (NYSE: NVO), a Denmark-based drugmaker, is currently a leader in the rapidly growing weight loss market. The company's Wegovy has practically become a household name, and it has plenty

Carnival (NYSE: CCL) has drawn investor interest for many reasons. Travel stocks remain popular, and the company's market lead in the cruise line industry and the continued strength in bookings

Do you want to swing for the fences with a promising growth stock to buy and hold? While many growth stocks may seem overpriced these days, you can find some decently priced mid-cap stocks, whose

On November 14, 2025, 5AM Venture Management, LLC, disclosed that it sold out its Viking Therapeutics stake, a move representing an estimated $5.02 million net position change.

According to a

Until a few weeks ago, I was more than happy to own shares in all three of the major cruise line stocks. Royal Caribbean (NYSE: RCL) was my largest of the three positions, followed by Carnival

There's nothing wrong with investing in well-known, market-leading corporations. Many still have excellent prospects and robust underlying businesses. However, it's also worth considering smaller

After the release of the top-line results from its phase 2 clinical trial of its lead drug candidate, VK2735 (oral formulation), in August, there were investors who doubted whether Viking

Eli Lilly (NYSE: LLY) produced exceptional returns over the long run and is now the largest pharmaceutical company in the world by market cap, largely thanks to its work in diabetes drugs and, more

Viking Therapeutics (NASDAQ: VKTX) leaped onto center stage early last year when it announced promising news about a candidate addressing an area of soaring demand: weight loss. The biotech then

It can take a while for growth stocks to reach their full potential, which is why they can make for good long-term options to hang on to. Along the way, however, they can encounter difficulties that

In common with many other small-cap biotech stocks, Viking Therapeutics' (NASDAQ: VKTX) share price tends to be volatile as investors react to the ebb and flow of news from the company. Today was an

Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) offer investors the chance to invest in one of today's highest-potential industries: weight loss drugs. The market for these products

Eli Lilly (NYSE: LLY) is the largest pharmaceutical (and healthcare) company in the world by market capitalization. It boasts more than 49,000 employees and currently leads the fast-growing market

Viking Therapeutics (NASDAQ: VKTX) soared to the forefront almost two years ago when it announced data on an investigational drug to serve an area of high need: weight loss. The biotech's candidate

Developing GLP-1 medicines is all the rage these days in the pharmaceutical and biotech industries. The market is growing rapidly, and many (if not most) leading drugmakers are looking to capitalize

The late investing legend Charlie Munger talked about a "fat-pitch strategy," a baseball analogy about waiting for a big, no-brainer opportunity you can take advantage of. When you get that fat

It's been a tough year for healthcare stocks. The broader industry has underperformed the market this year, at least as judged by major healthcare-focused exchange-traded funds, such as the Vanguard

The market was less than impressed with the top-line results from Viking Therapeutics' (NASDAQ: VKTX) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created

Viking Therapeutics (NASDAQ: VKTX) has intrigued investors over the past year and a half because it's involved in a potential David and Goliath story. Today, pharma giants Eli Lilly and Novo Nordisk

The biotech industry can be highly volatile. Companies in the sector can sometimes see their shares double in a short period due to hitting important clinical milestones. Over a more extended